位置:成果数据库 > 期刊 > 期刊详情页
穿膜融合多肽TAT-N24对S180腹水瘤生长的抑制作用
  • 期刊名称:华中科技大学学报(医学版)
  • 时间:0
  • 页码:369-371
  • 语言:中文
  • 分类:R349.6[医药卫生—基础医学]
  • 作者机构:[1]华中科技大学同济医学院附属同济医院分子医学中心,武汉430030
  • 相关基金:国家自然科学基金(No.30872472 No.30800569); 国家重点基础研究发展计划(No.200911b521802); 教育部新世纪优秀人才支持计划(No.NCET-04-0699)资助项目
  • 相关项目:p55PIK:一个新的结直肠癌分子治疗靶点
作者: 胡俊波|
中文摘要:

目的观察穿膜融合多肽TAT-N24对S180腹水瘤生长的抑制作用。方法建立S180腹水瘤小鼠模型,以不同剂量TAT-N24腹腔内注射,观察TAT-N24对腹水瘤小鼠腹水生成的影响,流式细胞仪检测腹水瘤细胞细胞周期进程,应用5-溴脱氧尿嘧啶核苷(BrdU)掺入法检测TAT-N24对细胞DNA合成的影响,验证TAT-N24的抗肿瘤作用。结果腹水测量结果显示,模型对照组腹水为(8.3±2.3)mL,实验组分别为:TAT-N245μL组(3.2±1.2)mL,TAT-N2420μL组(2.7±1.0)mL,TAT-N24100μL组(1.3±0.2)mL;结果提示给予腹腔注射TAT-N24能显著抑制腹水的生成(P〈0.05);BrdU/PI双掺入法检测细胞DNA合成结果显示,对照组BrdU阳性细胞数占总细胞比例为(25.86±3.54)%,而给予TAT-N24高剂量(100μL)组BrdU阳性细胞数占总细胞比例为(5.91±0.57)%,2组间差异有统计学意义(P〈0.01);对照组动物腹水瘤细胞中G0/G1期细胞为(63.88±4.01)%,S期和G2/M期细胞分别为(23.93±2.91)%和(12.19±1.62)%,而TAT-N24高剂量组动物腹水瘤细胞G0/G1期细胞增加至(83.71±1.53)%,S期和G2/M期细胞分别为(7.56±1.40)%和(8.72±0.73)%,2组比较差异有统计学意义(P〈0.01)。结论融合多肽TAT-N24能有效抑制S180腹水瘤小鼠的腹水生成,阻滞腹水瘤细胞细胞周期进程,抑制细胞DNA合成。

英文摘要:

Objective To elucidate the inhibitory effects of the cell-permeable TAT-N24 fusion peptide on the growth ability of S180 ascites tumor.Methods The murine S180 ascites tumor model was established.Different doses of TAT-N24 were injected intraperitoneally,and the effects of TAT-N24 on the ascites formation were observed.The cell cycle of S180 ascites tumor was assayed by flow cytometry.5-bromodeoxyuridine(BrdU/PI)incorporation method was applied to detect DNA synthesis in the tumor cells to clarify the anti-tumor role of TAT-N24.Results In model control group,the volume of ascites was(8.3±2.3)mL,and that in the experiment groups was(3.2±1.2)mL(TAT-N24 5 μL),(2.7±1.0)mL(TAT-N24 20 μL),(1.3±0.2)mL(TAT-N24 100 μL),respectively.In the control group the percentage of BrdU positive cells was(25.86±3.54)%,and that in the experiment group(TAT-N24 100 μL)was(5.91±0.57)% with the significant difference between two groups(P〈0.01).Cell cycle analysis revealed that the proportion of cells in G0/G1,S and G2/M phases was(63.88±4.01)%,(23.93±2.91)% and(12.19±1.62)% respectively in control group.However in TAT-N24 group,the proportion of cells in G0/G1,S and G2/M phases was(83.71±1.53)%,(7.56±1.40)% and(8.72±0.73)% respectively.There was significant difference between TAT-N24 group and control group(P〈0.01).Conclusion TAT-N24 fusion peptide can induce cell cycle arrest,inhibit the DNA synthesis of tumor cells and suppress tumor growth in murine S180 ascites tumor model.

同期刊论文项目
同项目期刊论文